PTO/SB/30 (03-09)

Under the Paperwork Reduction Act of 1995, no persons are requis	U.S. Patent and Tr	Approved for use through 04/30/2009, OMB 0651-0031 ademark Office, U.S. DEPARTMENT OF COMMERCE rmation unless it contains a valid OMB control number.	
Request	Application Number	10/764,311	
for (DOE)	Filing Date	January 23, 2004	
Continued Examination (RCE) Transmittal	First Named Inventor	Lubatschowski, Holger	
Address to: Mail Stop RCE Commissioner for Patents	Art Unit	3769	
	Examiner Name	FARAH, Ahmed M.	
P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket Number	3968-106	
This is a Request for Continued Examination (RCE) to	under 37 CFR 1.114 of the	above-identified application.	
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.			
1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be metered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked. L. Consider the arguments in the Appeal Brief or Reply Brief previously filed on			
b. Enclosed			
I Amendment/Reply iii Information Disclosure Statement (IDS)			
ii. Affidavit(s)/ Declaration(s) iv. Other			
2. Miscellaneous Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of			
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filled. The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 14-1137			
i. CE fee required under 37 CFR 1.17(e)			
ii. Extension of time fee (37 CFR 1 136 and 1.17)			
	Other Check in the amount of \$ enclosed		
b. Check in the amount of \$enclosed c. \[\] Payment by credit card (Form PTO-2038 enclosed)			
WARNING: Information on this form gray become public. Credificard information should not be included on this form. Provide credit card information and authorization on Provide Credit card information and authorization on Provide Credit card information and authorization of Pro-2038.			
SIGNATURE OF RPPLICANT, ATTORNEY, OR AGENT REQUIRED			
Signature /		ate May 4, 2010	
Name (Print/Type) GREGØRY M/LEFKOWITZ	7 R	egistration No. 56,216	
CERTIFICATÉ ØF MAILING OR TRANSMISSION			
I hereby certify that this correspondence is being deposited with the Junited States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Slop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the dates shown below.			
Office on the date shown below: Signature			
Name (Print/Type)	Dat	,	

Name (Priorffype)

This collection of information is required by 37 GFR 1,114. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 GFR 1,11 and 1.14. This collection is estimated to take 12 minutes to complete including patientially reporting and substrainting the completed application in the USPTO. Time will very depending upon the including latenary application for the USPTO. Time will very depending upon the including latenary and provided in the property of the provided provided in the USPTO. The will very depending upon the including latenary and provided provided in the USPTO. The will very depending upon the including latenary and provided in the USPTO. The will be used to be complete this form and/or supprison for reducing this bottom, about the use of the USPTO. The will be used to be used to be used to be completed to the Clinical Complete in the USPTO. The very depending upon the including latenary and the USPTO. The very depending upon the including latenary and the use of the USPTO. The very depending upon the including latenary and the use of the USPTO. The very depending upon the including latenary and the use of the USPTO. The very depending upon the including latenary and the USPTO. The very depending upon the including latenary and the USPTO. The very depending upon the including latenary and the USPTO. The very depending upon the including latenary and the USPTO. The very depending upon the including latenary and the USPTO. The very depending upon the including latenary and the use of the USPTO. The USPTO. The very depending upon the including latenary and the USPTO. The very depending upon the including latenary and the USPTO. The very depending upon the including latenary and the USPTO. The very depending upon the including latenary and the USPTO. The very depending upon the USPTO. The very depending upon the USPTO. The very depending upon the USPTO. The very